The clinical therapeutic effects of bispecific antibodies (BsAbs) are superior to those of monoclonal antibodies (MoAbs), with broad applications for tumor immunotherapy as well as for the treatment of other diseases. Recently, with progress in antibody engineering, various platforms for generating different types of BsAbs based on novel strategies, for various uses, have been established. More than 30 mature commercial technology platforms have been used to create and develop BsAbs. Seven BsAbs have received market approval, and more than 110 types of BsAbs are at various stages of clinical trials. Despite the clinical success, there are many challenges in developing bispecific antibodies.
In the following presentation, challenges, and new technology platforms for making bispecific antibodies as well as a discovery process of market-approved bispecific antibodies will be reviewed. Specifically, case studies on how to apply AI and computer-aided design to 1) optimize bispecific antibodies for safety, efficacy, and manufacture-ability balance; 2) enable Fc effector function for T cell engager; 3) enable co-internalization of a non-internalizing cancer-specific antigen for BsAb-ADC development; 4) enable an antibody to have enzymatic function will be introduced.
Key learnings:
• Challenges in making bispecific antibodies
• Emerging new technologies for making bispecific antibodies
• Case studies on how to apply AI/computer-aided design to make complex multi-specific antibodies
Speaker:
Dr. Yue Liu has more than 20 years of experience in therapeutic antibody development. She has led and participated in multiple therapeutic antibody studies on various diseases. In 2017, Dr. Liu founded Ab Studio Inc. (www.antibodystudio.com) and led the ABS team developed four unique technology platforms: 1) “Imbalanced” bispecific antibody platform and multi-specific antibody platform; 2) Fc enabled T cell engager platform; 3) “Serial” internalizing antibody platform; 4) “Catalytic” antibody platform and 5) “Humanized” llama VHH phage display platform. Since founded, Ab Studio has licensed out 5 bispecific antibodies and 1 tri-specific antibodies to BioPharma companies. Among these programs, GB261, which is a computer-designed, Fc-enabled CD20/CD3 T cell engager has entered the clinical phase I/II stage and showed POC of safety/efficacy balance.
Follow us on our socials:
LinkedIn: / sino
Twitter: / sinoinc
Facebook: / sinobiological
Visit Sino Biological: www.sinobiolog...
21 окт 2024
